Aida Tayebi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aida Tayebi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ozlem Ozmen Garibay
University of Central Florida
4 shared publications - Ali Khodabandeh Yalabadi
Department of Industrial Engineering University of Central Florida Orlando 32816 FL
3 shared publications - Mehdi Yazdani-Jahromi
Department of Computer Science University of Central Florida Orlando 32816 FL
3 shared publications - Niloofar Yousefi
University of Central Florida
3 shared publications - Sina Abdidizaji
University of Central Florida
2 shared publications
Latest Publications
- 30 May 2025
- Published by Springer Nature
- p. 117-127
Evaluating Fairness and Bias in Large Language Models for Tabular Data
- 30 May 2025
- Published by Springer Nature
- p. 117-127
Evaluating Fairness and Bias in Large Language Models for Tabular Data
- 1 June 2024
- Published by Springer Nature
- p. 105-115
Learning Fair Representations: Mitigating Statistical Dependencies
- 1 June 2024
- Published by Springer Nature
- p. 105-115
Learning Fair Representations: Mitigating Statistical Dependencies
- 17 May 2024
- Published by Springer Nature
- p. 68-85
FragXsiteDTI: Revealing Responsible Segments in Drug-Target Interaction with Transformer-Driven Interpretation
- 17 May 2024
- Published by Springer Nature
- p. 68-85
FragXsiteDTI: Revealing Responsible Segments in Drug-Target Interaction with Transformer-Driven Interpretation
- Open Access
FragXsiteDTI: Revealing Responsible Segments in Drug-Target Interaction with Transformer-Driven Interpretation
Drug-Target Interaction (DTI) prediction is vital for drug discovery, yet challenges persist in achieving model interpretability and optimizing performance. We propose a novel transformer-based model, FragXsiteDTI, that aims to address these challenges in DTI prediction. Notably, FragXsiteDTI is the first DTI model to simultaneously leverage drug molecule fragments and protein pockets. Our information-rich representations for both proteins and drugs offer a detailed perspective on their interaction. Inspired by the Perceiver IO framework, our model features a learnable latent array, initially interacting with protein binding site embeddings using cross-attention and later refined through self-attention and used as a query to the drug fragments in the drug's cross-attention transformer block. This learnable query array serves as a mediator and enables seamless information translation, preserving critical nuances in drug-protein interactions. Our computational results on three benchmarking datasets demonstrate the superior predictive power of our model over several state-of-the-art models. We also show the interpretability of our model in terms of the critical components of both target proteins and drug molecules within drug-target pairs.
Open AccessFragXsiteDTI: Revealing Responsible Segments in Drug-Target Interaction with Transformer-Driven Interpretation
Drug-Target Interaction (DTI) prediction is vital for drug discovery, yet challenges persist in achieving model interpretability and optimizing performance. We propose a novel transformer-based model, FragXsiteDTI, that aims to address these challenges in DTI prediction. Notably, FragXsiteDTI is the first DTI model to simultaneously leverage drug molecule fragments and protein pockets. Our information-rich representations for both proteins and drugs offer a detailed perspective on their interaction. Inspired by the Perceiver IO framework, our model features a learnable latent array, initially interacting with protein binding site embeddings using cross-attention and later refined through self-attention and used as a query to the drug fragments in the drug's cross-attention transformer block. This learnable query array serves as a mediator and enables seamless information translation, preserving critical nuances in drug-protein interactions. Our computational results on three benchmarking datasets demonstrate the superior predictive power of our model over several state-of-the-art models. We also show the interpretability of our model in terms of the critical components of both target proteins and drug molecules within drug-target pairs.